Halozyme Q4 revenue up 52% to $451.8 million; net loss of $141.6 million
Halozyme reported fourth-quarter 2025 total revenue of $451.8 million, up 52% from a year earlier, but a net loss of $141.6 million, which included $284.9 million of acquired in-process R&D expense tied to the Surf Bio acquisition. For full-year 2025, total revenue rose 38% to $1.4 billion, and the company reiterated its 2026 guidance for total revenue of $1.710 billion to $1.810 billion and non-GAAP diluted EPS of $7.75 to $8.25.
Key points
- Q4 2025 total revenue was $451.8 million versus $298.0 million in Q4 2024; royalties were $258.0 million, up 51%.
- Q4 2025 net loss was $141.6 million versus net income of $137.0 million a year earlier; GAAP diluted loss was $1.20 per share.
- Full-year 2025 total revenue was $1,396.6 million, up 38%, with royalty revenue of $867.8 million, up 52%.
- 2026 guidance reiterated: total revenue of $1.710 billion to $1.810 billion and non-GAAP diluted EPS of $7.75 to $8.25, last updated January 28, 2026.
The filing
Written by AI on Nov 8, 2026, 1:12 AM ET, from this filing only. Written later: this filing was briefed after the fact, when past filings were added to the site, so the brief may be read with hindsight; the filing itself is the record of what was known on February 17, 2026.
Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.